BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
10.37
-0.03 (-0.29%)
At close: Jun 13, 2025, 4:00 PM
10.25
-0.12 (-1.16%)
After-hours: Jun 13, 2025, 7:27 PM EDT
BioCryst Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 8 professional analysts, the 12-month price target for BioCryst Pharmaceuticals stock ranges from a low of $11 to a high of $30. The average analyst price target of $16.75 forecasts a 61.52% increase in the stock price over the next year.
Price Target: $16.75 (+61.52%)
Analyst Consensus: Buy
* Price targets were last updated on May 7, 2025.
Analyst Ratings
The average analyst rating for BioCryst Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 4 | 5 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Hold Maintains $8 → $11 | Hold | Maintains | $8 → $11 | +6.08% | May 7, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $11 → $13 | Buy | Reiterates | $11 → $13 | +25.36% | May 6, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $10 → $13 | Buy | Maintains | $10 → $13 | +25.36% | May 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +189.30% | May 6, 2025 |
| Needham | Needham | Strong Buy Maintains $15 → $17 | Strong Buy | Maintains | $15 → $17 | +63.93% | May 6, 2025 |
Financial Forecast
Revenue This Year
626.68M
from 450.71M
Increased by 39.04%
Revenue Next Year
709.80M
from 626.68M
Increased by 13.26%
EPS This Year
0.03
from -0.43
EPS Next Year
0.38
from 0.03
Increased by 1,136.66%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 661.4M | 775.7M | 895.7M | ||
| Avg | 626.7M | 709.8M | 794.8M | ||
| Low | 588.1M | 643.2M | 693.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 46.7% | 23.8% | 26.2% | ||
| Avg | 39.0% | 13.3% | 12.0% | ||
| Low | 30.5% | 2.6% | -2.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.37 | 0.89 | 1.58 | ||
| Avg | 0.03 | 0.38 | 0.85 | ||
| Low | -0.26 | 0.04 | 0.36 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 2,784.9% | 311.7% | ||
| Avg | - | 1,136.7% | 121.2% | ||
| Low | - | 26.7% | -5.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.